Cargando…
Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
Autores principales: | Capuano, Rocco, Donnarumma, Giovanna, Bisecco, Alvino, Grimaldi, Elena, Conte, Miriana, d’Ambrosio, Alessandro, Matrone, Federica, Risi, Mario, Borgo, Riccardo Maria, Altieri, Manuela, Giuliano, Federica, Coppola, Nicola, Galdiero, Massimiliano, Tedeschi, Gioacchino, Gallo, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369851/ https://www.ncbi.nlm.nih.gov/pubmed/34413902 http://dx.doi.org/10.1177/17562864211038111 |
Ejemplares similares
-
Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
por: Altieri, Manuela, et al.
Publicado: (2022) -
Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021) -
Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021) -
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022) -
Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)